Amgen has completed its first next-gen biomanufacturing facility in Singapore encompassing multiple technologies aimed at enabling greater speed, productivity and flexibility in commercial-scale manufacturing.
 
The new Taus facility uses single-use bioreactors, disposable plastic containers, continuous purification processing and real-time quality analysis, and, according to the company, was completed in half the time required for conventional biomanufacturing plants. This flexible, modular design can be replicated in future facilities, enabling higher production and greater accessibility to patients globally.
 
The facility is expected to have the same annual output as a conventional facility but in a single building that will use fewer resources. The company also plans to build another facility at its Tuas site in Singapore to make carfilzomib, the active ingredient for Kyprolis.
 
“At Amgen, we are reinventing what it means to manufacture biologic medicines,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “Singapore is an ideal place to invest in such a pioneering facility because of its talented workforce and commitment to the biotechnology industry.”